HW
HighMark Wealth Management LLC
13F filer · CIK 0001802451Reported Aug 12, 2026
Net seller this quarter
13F portfolio value$299MU.S. long equity reported on 13F
Positions43534 new · 33 closed
Net flow last quarter-$2.41MBuys minus sells
Top 10 positions weight19.2%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 12, 2026435 positions | |||||
| $15.8M | 5.28% | 0.64% | -1.0% | Q3 2020 | |
| $8.94M | 2.99% | 0.48% | +5.6% | Q2 2020 | |
| $6.94M | 2.32% | 0.95% | +165.9% | Q1 2020 | |
| $5.67M | 1.90% | 0.00% | +0.1% | Q4 2019 | |
| ATAPGEApogee Therapeutics, Inc. | $4.28M | 1.43% | 0.04% | New | Q2 2026 |
| $4.02M | 1.35% | 0.06% | -0.7% | Q4 2024 | |
| $3.48M | 1.17% | 1.42% | New | Q2 2026 | |
| $2.96M | 0.99% | 0.89% | +6.4% | Q4 2025 | |
| $2.68M | 0.90% | 0.14% | -71.9% | Q1 2025 | |
| $2.59M | 0.87% | 0.48% | +158.7% | Q3 2024 | |
| $2.37M | 0.79% | 0.00% | -7.3% | Q4 2019 | |
| $2.34M | 0.78% | 0.16% | Not reported | Q2 2020 | |
| $2.2M | 0.74% | 0.00% | -3.0% | Q4 2019 | |
| $2.16M | 0.72% | 0.05% | Not reported | Q4 2024 | |
| $2.08M | 0.70% | 0.00% | +0.4% | Q4 2019 | |
| $1.85M | 0.62% | 0.00% | +0.6% | Q4 2019 | |
| $1.75M | 0.59% | 0.00% | +4.0% | Q4 2019 | |
| $1.73M | 0.58% | 1.17% | -3.5% | Q2 2020 | |
| $1.58M | 0.53% | 0.00% | -0.3% | Q4 2019 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $1.44M | 0.48% | 0.04% | +88.3% | Q4 2023 |
| $1.39M | 0.47% | 0.02% | Not reported | Q1 2024 | |
| $1.19M | 0.40% | 0.00% | 0.0% | Q4 2019 | |
| $1.05M | 0.35% | 0.00% | +0.5% | Q4 2019 | |
| $1.01M | 0.34% | 0.00% | -1.9% | Q4 2019 | |
| $857K | 0.29% | 0.00% | Not reported | Q4 2019 | |
| $807K | 0.27% | Not reported | -3.7% | Q4 2019 | |
| $784K | 0.26% | 0.00% | +8.2% | Q4 2019 | |
| $764K | 0.26% | 0.00% | +1.4% | Q4 2019 | |
| $711K | 0.24% | 0.00% | +5.2% | Q4 2019 | |
| $597K | 0.20% | 0.03% | Not reported | Q4 2019 | |
| $585K | 0.20% | 0.00% | +0.3% | Q4 2019 | |
| $568K | 0.19% | 0.00% | +1.6% | Q4 2019 | |
| $515K | 0.17% | 0.05% | Not reported | Q4 2019 | |
| $508K | 0.17% | 0.26% | Not reported | Q4 2019 | |
| $458K | 0.15% | 0.03% | Not reported | Q1 2021 | |
| $438K | 0.15% | 0.00% | +0.8% | Q4 2019 | |
| $435K | 0.15% | Not reported | +1.7% | Q4 2019 | |
| $425K | 0.14% | 0.00% | -1.0% | Q4 2019 | |
| $387K | 0.13% | 0.00% | Not reported | Q4 2019 | |
| $387K | 0.13% | 0.00% | -5.5% | Q4 2019 | |
| $379K | 0.13% | 0.00% | +15.5% | Q1 2021 | |
| $368K | 0.12% | 0.00% | Not reported | Q4 2019 | |
| $365K | 0.12% | 0.38% | +69.1% | Q4 2024 | |
| $353K | 0.12% | 0.00% | +11.5% | Q2 2022 | |
| $343K | 0.11% | 0.00% | Not reported | Q3 2021 | |
| $322K | 0.11% | 0.00% | Not reported | Q1 2023 | |
| $320K | 0.11% | Not reported | +0.5% | Q4 2019 | |
| $303K | 0.10% | Not reported | -6.7% | Q3 2025 | |
| $299K | 0.10% | 0.00% | -8.6% | Q4 2019 | |
| $297K | 0.10% | 0.00% | -5.2% | Q1 2020 | |
| Q1 2026Reported May 6, 2026434 positions | |||||
| $11.4M | 4.65% | 0.65% | +0.3% | Q3 2020 | |
| CPCNTACentessa Pharmaceuticals PLC | $9.41M | 3.83% | 0.15% | Not reported | Q2 2024 |
| $5.46M | 2.22% | 0.00% | 0.0% | Q4 2019 | |
| $5.22M | 2.12% | 0.32% | Not reported | Q1 2025 | |
| $4.3M | 1.75% | 0.45% | +2.2% | Q2 2020 | |
| $2.39M | 0.97% | 0.17% | Not reported | Q2 2020 | |
| $2.23M | 0.91% | 0.00% | +10.0% | Q4 2019 | |
| $2.02M | 0.82% | 0.36% | Not reported | Q1 2020 | |
| $1.99M | 0.81% | 0.00% | -1.1% | Q4 2019 | |
| $1.95M | 0.80% | 0.85% | +32.5% | Q4 2025 | |
| $1.87M | 0.76% | 0.06% | -0.4% | Q4 2024 | |
| $1.68M | 0.68% | 0.05% | Not reported | Q4 2024 | |
| $1.66M | 0.68% | 0.00% | +21.5% | Q4 2019 | |
| $1.63M | 0.66% | 0.00% | -0.2% | Q4 2019 | |
| $1.59M | 0.65% | 0.00% | +0.5% | Q4 2019 | |
| $1.42M | 0.58% | 0.00% | +0.3% | Q4 2019 | |
| $1.34M | 0.54% | 0.02% | Not reported | Q1 2024 | |
| $1.21M | 0.49% | 0.02% | New | Q1 2026 | |
| $1.13M | 0.46% | 1.22% | +21.8% | Q2 2020 | |
| $1.05M | 0.43% | 0.00% | -1.7% | Q4 2019 | |
| $1.04M | 0.42% | 0.00% | +0.5% | Q4 2019 | |
| $883K | 0.36% | 0.00% | +0.4% | Q4 2019 | |
| $828K | 0.34% | 0.19% | Not reported | Q3 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $744K | 0.30% | 0.02% | -4.7% | Q4 2023 |
| $743K | 0.30% | 0.00% | Not reported | Q4 2019 | |
| $742K | 0.30% | 0.00% | -1.2% | Q4 2019 | |
| $729K | 0.30% | Not reported | -16.0% | Q4 2019 | |
| $718K | 0.29% | 0.24% | Not reported | Q2 2025 | |
| $654K | 0.27% | 0.05% | -2.9% | Q4 2019 | |
| $591K | 0.24% | 0.00% | +32.1% | Q4 2019 | |
| $583K | 0.24% | 0.00% | +76.9% | Q4 2019 | |
| $576K | 0.23% | 0.03% | -2.3% | Q1 2021 | |
| $557K | 0.23% | 0.00% | +0.2% | Q4 2019 | |
| $533K | 0.22% | 0.00% | -3.9% | Q4 2019 | |
| $522K | 0.21% | 0.26% | Not reported | Q4 2019 | |
| $522K | 0.21% | 0.03% | -1.4% | Q4 2019 | |
| $513K | 0.21% | 0.00% | +1.9% | Q4 2019 | |
| $438K | 0.18% | 0.00% | -1.4% | Q4 2019 | |
| $436K | 0.18% | 0.00% | -5.6% | Q4 2019 | |
| $403K | 0.16% | 0.00% | +406.5% | Q4 2019 | |
| $397K | 0.16% | 0.00% | +69.3% | Q2 2022 | |
| $347K | 0.14% | Not reported | +0.1% | Q4 2019 | |
| $275K | 0.11% | 0.00% | -1.2% | Q3 2021 | |
| $269K | 0.11% | 0.00% | +543.7% | Q1 2021 | |
| $258K | 0.10% | 0.23% | +18.2% | Q4 2024 | |
| $256K | 0.10% | 0.00% | -0.7% | Q2 2024 | |
| $250K | 0.10% | Not reported | -2.5% | Q4 2019 | |
| $248K | 0.10% | 0.00% | Not reported | Q1 2023 | |
| $245K | 0.10% | 0.00% | Not reported | Q4 2019 | |
| $242K | 0.10% | 0.00% | Not reported | Q4 2019 | |
| Q4 2025Reported Feb 5, 2026447 positions | |||||
| $11.3M | 4.59% | 0.73% | +85.8% | Q3 2020 | |
| $6.67M | 2.72% | 0.44% | +41.7% | Q2 2020 | |
| $6.39M | 2.61% | 0.00% | -8.3% | Q4 2019 | |
| CPCNTACentessa Pharmaceuticals PLC | $5.92M | 2.41% | 0.16% | -0.2% | Q2 2024 |
| $4.56M | 1.86% | 0.34% | -30.4% | Q1 2025 | |
| $3.31M | 1.35% | 0.17% | 0.0% | Q2 2020 | |
| $3.15M | 1.28% | 0.37% | +549.7% | Q1 2020 | |
| $2.17M | 0.88% | 0.00% | -1.0% | Q4 2019 | |
| $2.15M | 0.88% | 0.00% | -5.8% | Q4 2019 | |
| $1.85M | 0.75% | 0.00% | +0.1% | Q4 2019 | |
| $1.79M | 0.73% | 0.00% | +0.9% | Q4 2019 | |
| $1.77M | 0.72% | 1.03% | +139.0% | Q2 2020 | |
| $1.62M | 0.66% | 0.00% | +0.2% | Q4 2019 | |
| $1.57M | 0.64% | 0.24% | +3.4% | Q2 2025 | |
| $1.56M | 0.64% | 0.00% | -0.3% | Q4 2019 | |
| $1.32M | 0.54% | 0.05% | Not reported | Q4 2024 | |
| $1.3M | 0.53% | 0.00% | +0.1% | Q4 2019 | |
| $1.27M | 0.52% | 0.66% | New | Q4 2025 | |
| $1.25M | 0.51% | 0.06% | Not reported | Q4 2024 | |
| $1.14M | 0.46% | 0.04% | -42.5% | Q1 2021 | |
| $1.03M | 0.42% | 0.03% | -11.9% | Q1 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $1M | 0.41% | 0.02% | +7.5% | Q4 2023 |
| $973K | 0.40% | 0.19% | Not reported | Q3 2024 | |
| $960K | 0.39% | 0.00% | +0.5% | Q4 2019 | |
| $910K | 0.37% | Not reported | +13.3% | Q4 2019 | |
| $902K | 0.37% | 0.00% | +0.5% | Q4 2019 | |
| $772K | 0.31% | 0.05% | +49.0% | Q4 2019 | |
| $745K | 0.30% | 0.00% | +0.7% | Q4 2019 | |
| $709K | 0.29% | 0.00% | Not reported | Q4 2019 | |
| $703K | 0.29% | 0.26% | Not reported | Q4 2019 | |
| $569K | 0.23% | 0.03% | -5.3% | Q4 2019 | |
| $549K | 0.22% | 0.00% | +0.1% | Q4 2019 | |
| $542K | 0.22% | 0.00% | +0.5% | Q4 2019 | |
| $495K | 0.20% | 0.00% | -16.0% | Q4 2019 | |
| $440K | 0.18% | 0.00% | +0.5% | Q4 2019 | |
| $400K | 0.16% | 0.00% | -4.7% | Q4 2019 | |
| $393K | 0.16% | 0.00% | +3.5% | Q4 2019 | |
| $380K | 0.15% | Not reported | Not reported | Q4 2019 | |
| $378K | 0.15% | 0.04% | Not reported | Q2 2024 | |
| $358K | 0.15% | 0.00% | +0.4% | Q4 2019 | |
| $293K | 0.12% | 0.00% | Not reported | Q1 2023 | |
| $286K | 0.12% | 0.00% | +20.1% | Q4 2019 | |
| $285K | 0.12% | 0.00% | +1.9% | Q2 2022 | |
| $283K | 0.12% | 0.00% | +0.4% | Q4 2019 | |
| $272K | 0.11% | Not reported | -2.2% | Q4 2019 | |
| $239K | 0.10% | 0.00% | +0.7% | Q2 2024 | |
| $237K | 0.10% | 0.00% | +1.2% | Q3 2021 | |
| $234K | 0.10% | 0.00% | +0.5% | Q2 2020 | |
| $229K | 0.09% | 0.00% | Not reported | Q4 2019 | |
| $209K | 0.08% | 0.28% | -22.0% | Q4 2023 | |
| Q3 2025Reported Oct 20, 2025471 positions | |||||
| $6.27M | 2.76% | 0.00% | 0.0% | Q4 2019 | |
| PHPHLTPerformant Healthcare, Inc. | $5.84M | 2.57% | Not reported | -7.0% | Q3 2021 |
| CPCNTACentessa Pharmaceuticals PLC | $5.75M | 2.53% | 0.18% | Not reported | Q2 2024 |
| $4.42M | 1.95% | 0.49% | -7.2% | Q1 2025 | |
| $3.3M | 1.45% | 0.40% | +88.7% | Q3 2020 | |
| $3.09M | 1.36% | 0.31% | +221.3% | Q2 2020 | |
| $2.95M | 1.30% | 0.17% | Not reported | Q2 2020 | |
| $2.19M | 0.96% | 0.00% | -10.3% | Q4 2019 | |
| $2.14M | 0.94% | 0.00% | +0.8% | Q4 2019 | |
| $1.9M | 0.84% | 0.00% | -1.2% | Q4 2019 | |
| $1.56M | 0.69% | 0.00% | +0.1% | Q4 2019 | |
| $1.52M | 0.67% | 0.00% | -0.4% | Q4 2019 | |
| $1.37M | 0.60% | 0.06% | -0.3% | Q1 2021 | |
| $1.31M | 0.58% | 0.00% | Not reported | Q4 2019 | |
| $1.28M | 0.56% | 0.00% | +10.9% | Q4 2019 | |
| $1.24M | 0.54% | 0.23% | Not reported | Q2 2025 | |
| $1.11M | 0.49% | 0.07% | +2.5% | Q4 2024 | |
| $1.05M | 0.46% | 0.03% | Not reported | Q1 2024 | |
| $1.04M | 0.46% | 0.00% | +0.6% | Q4 2019 | |
| $884K | 0.39% | 0.44% | +88.3% | Q2 2020 | |
| $863K | 0.38% | 0.05% | +2.1% | Q4 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $833K | 0.37% | 0.02% | Not reported | Q4 2023 |
| $828K | 0.36% | 0.00% | -4.3% | Q4 2019 | |
| $813K | 0.36% | 0.00% | +0.5% | Q4 2019 | |
| $793K | 0.35% | 0.00% | +0.4% | Q4 2019 | |
| $785K | 0.35% | Not reported | -0.9% | Q4 2019 | |
| $650K | 0.29% | 0.19% | Not reported | Q3 2024 | |
| $639K | 0.28% | 0.00% | Not reported | Q4 2019 | |
| $577K | 0.25% | 0.00% | +0.3% | Q4 2019 | |
| $572K | 0.25% | 0.00% | +0.2% | Q4 2019 | |
| $557K | 0.25% | 0.00% | -28.5% | Q4 2019 | |
| $501K | 0.22% | 0.00% | +0.8% | Q4 2019 | |
| $463K | 0.20% | 0.26% | Not reported | Q4 2019 | |
| $460K | 0.20% | 0.00% | -2.8% | Q4 2019 | |
| $425K | 0.19% | 0.04% | Not reported | Q3 2024 | |
| $417K | 0.18% | 0.03% | +73.8% | Q4 2019 | |
| $390K | 0.17% | 0.04% | +5.4% | Q2 2024 | |
| $362K | 0.16% | 0.06% | Not reported | Q1 2020 | |
| $356K | 0.16% | 0.00% | +1.5% | Q4 2019 | |
| $344K | 0.15% | 0.00% | +2.7% | Q4 2019 | |
| $324K | 0.14% | 0.36% | +55.3% | Q4 2023 | |
| $294K | 0.13% | Not reported | -7.8% | Q4 2019 | |
| $292K | 0.13% | 0.00% | Not reported | Q1 2023 | |
| $287K | 0.13% | 0.00% | +7.6% | Q2 2022 | |
| $286K | 0.13% | 0.03% | -0.4% | Q4 2019 | |
| $277K | 0.12% | 0.00% | Not reported | Q4 2019 | |
| $275K | 0.12% | 0.00% | -1.4% | Q4 2019 | |
| $272K | 0.12% | Not reported | +7.9% | Q4 2019 | |
| $249K | 0.11% | 0.00% | +73.1% | Q4 2019 | |
| $240K | 0.11% | 0.00% | Not reported | Q2 2024 | |
Premium opens every quarter this fund has filed